Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sayaka Onoda"'
Autor:
Sayaka Onoda, Takayuki Kuriyama, Akira Yokoyama, Akihiro Tagawa, Noriyuki Masuda, Koshiro Watanabe, Masao Harada, Hiroaki Okamoto, Takashi Ogura, Nobuhiko Seki, Yoshiko Asaka-Amano, Kazutsugu Uematsu, Kenji Eguchi, Hiroshi Kunikane, Hiroshi Isobe, Yumi Kuroiwa, Takashi Seto, Masanori Yokoba, Yuichi Takiguchi
Publikováno v:
Journal of Clinical Oncology. 24:5448-5453
Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods SCLC patients with measurable disease who h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62dc31d12022af5fd4d2468a5bbf2a7c
https://doi.org/10.1200/jco.2006.08.4145
https://doi.org/10.1200/jco.2006.08.4145
Autor:
Hirosuke Kobayashi, Hisashi Mitsufuji, Susumu Arai, Noriyuki Masuda, Masaru Kubota, Shinichiro Ryuge, Sayaka Onoda, Masanori Yokoba, Michiko Yamamoto, Nobuo Yanase, Tomoko Yanaihara, Tadashi Abe, Masato Katagiri, Mayuko Wada, Shintaro Hagiri
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:419-427
We conducted a Phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor. The aim was to determine the maximum tolerated dose (MTD) of amrubicin combined with a fixed dose of CPT-11 as we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e91c82a60ed4c51ed94e3762c6c9a68
https://doi.org/10.1007/s00280-006-0279-5
https://doi.org/10.1007/s00280-006-0279-5
Autor:
Kaori Ishii, Emi Kato, Shintaro Hagiri, Mayumi Wada, Hisashi Mitsufuji, Tadashi Abe, Michiko Yamamoto, Tomoko Yanaihara, Masato Katagiri, Nobuo Yanase, Noriyuki Masuda, Naohiko Tanaka, Hirosuke Kobayashi, Sayaka Onoda, Nobukazu Takada, Masaru Kuboto, Shinichiro Ryuge, Masanori Yokoba
Publikováno v:
Japanese Journal of Clinical Oncology. 35:478-482
Gefitinib is a synthetic, oral anilinoquinazoline specifically designed to inhibit the epidermal growth factor receptor tyrosine kinase, and is the first targeted drug to demonstrate reproducible activity in non-small cell lung cancer patients who do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bee728255bfefec9c34ac2635a92da5
https://doi.org/10.1093/jjco/hyi122
https://doi.org/10.1093/jjco/hyi122
[A case of recurrent invasive thymic cancer showing a stable disease to carboplatin plus paclitaxel]
Autor:
Satoshi, Igawa, Nobuyuki, Yanagisawa, Shinichi, Makita, Yuichiro, Iida, Sachiyo, Maki, Yuka, Kimura, Sakiko, Otani, Nobuatsu, Hayashi, Akira, Takakura, Ken, Katono, Sayaka, Onoda, Michiko, Yamamoto, Noriyuki, Masuda
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 37(11)
A 56-year-old man was admitted to our hospital because of increasing chest discomfort and abnormal chest shadow. Computed tomography (CT) of the chest revealed an anterior mediastinal mass, pleural dissemination and lung metastasis. Percutaneus needl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6d4895b788d7acd982e8e89bfb863937
https://pubmed.ncbi.nlm.nih.gov/21084818
https://pubmed.ncbi.nlm.nih.gov/21084818
Autor:
Susumu Arai, Akira Takakura, Hisashi Mitsufuji, Hirosuke Kobayashi, Sayaka Onoda, Masaru Kubota, Ryuji Hataishi, Maiko Iwasaki, Nobuo Yanase, Noriyuki Masuda, Yasuto Nishii, Ken Katono, Mayuko Wada, Tomoko Yanaihara, Sakiko Otani, Masato Katagiri, Michiko Yamamoto, Tomoya Fukui, Shinichiro Ryuge, Masanori Yokoba
Publikováno v:
International journal of clinical oncology. 14(4)
Despite the literature indicating adverse interactions between warfarin and cytotoxic agents, whether such an interaction occurs when warfarin and gefitinib are used concomitantly is unknown. We analyzed the prevalence of the concomitant use of warfa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32499cad3a7d65027f4468b433bef2de
https://pubmed.ncbi.nlm.nih.gov/19705244
https://pubmed.ncbi.nlm.nih.gov/19705244
Autor:
Hisashi Mitsufuji, Noriyuki Masuda, Yasuto Nishii, Sayaka Onoda, Shinichiro Ryuge, Masanori Yokoba, Maiko Iwasaki, Takashi Asahara, Ken Katono, Akira Takakura, Tomoya Fukui, Michiko Yamamoto, Akinobu Kurita, Mayuko Wada, Tomoko Yanaihara
Publikováno v:
Oncology Reports. 20
One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its active metabolite, SN-38, which is conjugated by hepatic urid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f715efcd76e1a536ac93dab6f6fd02c
https://doi.org/10.3892/or_00000066
https://doi.org/10.3892/or_00000066
Autor:
N. Yanase, Sayaka Onoda, Noriyuki Masuda, E. Kato, Hisashi Mitsufuji, Shinichiro Ryuge, S. Hagiri, Mayuko Wada, Tomoko Yanaihara, Michiko Yamamoto
Publikováno v:
Journal of Clinical Oncology. 23:2070-2070
2070 Background: CPT-11 (topoisomerase I inhibitor) and AMR (topoisomerase II inhibitor) are active against several solid tumors including NSCLC. Based on the preclinical data, this phase I trial w...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3f73994f226085b1bbff5546bbbf21e
https://doi.org/10.1200/jco.2005.23.16_suppl.2070
https://doi.org/10.1200/jco.2005.23.16_suppl.2070